Author:
Skakun Oleksiy,Seredyuk Nestor,Fedorov Sergiy,Verbovska Olha
Abstract
Background/Aim: Although ferritin and haemoglobin were well-studied for adverse outcome prediction in COVID-19 patients, a ferritin-haemoglobin ratio (FHR) was studied poorly. The study aimed to evaluate the prognostic ability of FHR at hospital admission in hypertensive and non-hypertensive patients with COVID-19. Methods: The study included 135 patients hospitalised for COVID-19-associated pneumonia. The 78.5 % of patients were hypertensive. Results: FHR at admission was higher in patients with critical condition (39.8 [17.1-83.0]) than in patients with moderate (22.0 [12.1-32.1], p = 0.01) and severe condition (34.6 [15.1-64.5], p = 0.01). FHR was higher in patients who required supplemental oxygen (40.4 [29.4-47.8]) than in patients without the need for supplemental oxygen (22.0 [18.0-25.5]) (p = 0.001). FHR at admission was higher in non-survivors (40.1 [24.6-95.9]) than in survivors (24.5 [21.6-28.4]) (p = 0.047). FHR showed weak discriminative ability for the prediction of severe/critical conditions in hypertensive patients (AUC = 0.636, p = 0.015) and all (hypertensive and non-hypertensive patients) patients (AUC = 0.658, p = 0.001), whereas FHR had an acceptable discriminative ability in non-hypertensive patients (AUC = 0.764, p = 0.015). There was an acceptable discriminative ability of FHR for in-hospital mortality prediction in hypertensive patients (AUC = 0.717, p = 0.029). Patients with FHR > 33.98 (Youden index, 0.39) had higher odds of severe/critical clinical condition (OR: 4.57; 95 % CI: 1.87-11.18; p = 0.001). FHR of > 37.64 (Youden index, 0.55) was associated with higher in-hospital mortality among hypertensive patients (OR: 12.06; 95 % CI: 2.44-59.71; p = 0.002). There was no difference in AUC for the discriminative ability of FHR regarding severe/ critical condition (p = 0.296) and mortality (p = 0.663) in hypertensive and non-hypertensive patients. Conclusion: FHR at admission of > 33.98 is a predictor of severe/critical COVID-19 in both hypertensive and non-hypertensive patients. FHR of > 37.64 is a predictor of in-hospital mortality in hypertensive patients. There was no significant difference in the discriminative ability of FHR between hypertensive and non-hypertensive patients.
Publisher
Centre for Evaluation in Education and Science (CEON/CEES)
Subject
General Economics, Econometrics and Finance,General Medicine
Reference32 articles.
1. Panneer S, Kantamaneni K, Palaniswamy U, Bhat L, Pushparaj RRB, Nayar KR, et al. Health, economic and social development challenges of the COVID-19 pandemic: strategies for multiple and interconnected issues. Healthcare 2022;10(5):770. doi:10.3390/healthcare10050770;
2. WHO. WHO COVID-19 dashboard [Internet]. World Health Organization. 2023. Available from: https://covid19.who.int/ [Accessed 19-Jun-2023];
3. Alimohamadi Y, Tola HH, Abbasi-Ghahramanloo A, Janani M, Sepandi M. Case fatality rate of COVID-19: a systematic review and meta-analysis. J Prev Med Hyg 2021;62(2):E311-E320;
4. Tan LY, Komarasamy TV, Rmt Balasubramaniam V. Hyperinflammatory immune response and COVID-19: a double edged sword. Front Immunol 2021;12:742941. doi:10.3389/fimmu.2021.742941;
5. Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics 2014;6(4):748-73;